Valuation: ImmuCell Corporation

Market Cap 103M 93.78M 86.8M 78.27M 147M 9.62B 153M 1.04B 413M 5.19B 386M 378M 16.4B P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 112M 102M 94.71M 85.41M 161M 10.49B 167M 1.14B 451M 5.67B 421M 412M 17.9B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.83%
Yield 2024 *
-
Yield 2025 -
1 day-0.71%
1 week+10.40%
Current month+9.65%
1 month+4.65%
3 months+15.27%
6 months+13.52%
Current year+82.93%
1 week 10.5
Extreme 10.5
11.72
1 month 9.6
Extreme 9.6
11.72
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 2025-10-31
Director of Finance/CFO 47 2025-04-06
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 2013-11-30
Director/Board Member 61 2014-03-30
Director/Board Member 66 2020-06-09
Date Insider Type Main position Quantity % Market Cap. Importance
4/15/26 Free

Chairman

11,933 0.1319%
4/15/26 Free

Director

17,899 0.1979%
4/15/26 Free

Director

11,933 0.1319%
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%+10.40%+146.71%+136.28% 103M
-2.32%-3.79%+34.24%+133.69% 1,261B
-2.15%-2.75%+36.35%+82.05% 671B
-2.33%-3.04%+22.29%+106.80% 518B
-0.69%+0.40%+40.46%+69.78% 387B
-3.90%-6.39%+42.88%+35.41% 353B
-1.35%-2.23%+24.30%+56.34% 300B
-1.13%-1.80%+0.59%+33.00% 283B
-3.07%-5.17%+29.04%+67.26% 248B
-0.75%-0.44%+32.87%+123.96% 211B
Average -0.97%+0.85%+40.97%+84.46% 423B
Weighted average by Cap. -0.77%-0.55%+31.08%+91.57%

Financials

2024 2025
Net sales 26.49M 24.14M 22.35M 20.15M 37.97M 2.48B 39.45M 269M 106M 1.34B 99.38M 97.3M 4.22B 27.64M 25.19M 23.32M 21.03M 39.62M 2.58B 41.16M 281M 111M 1.39B 104M 102M 4.41B
Net income -2.16M -1.97M -1.82M -1.64M -3.09M -202M -3.21M -21.89M -8.66M -109M -8.09M -7.92M -344M -1.04M -948K -877K -791K -1.49M -97.2M -1.55M -10.56M -4.18M -52.47M -3.9M -3.82M -166M
Net Debt 11.34M 10.34M 9.57M 8.63M 16.25M 1.06B 16.89M 115M 45.56M 572M 42.54M 41.66M 1.81B 9.39M 8.56M 7.92M 7.14M 13.45M 877M 13.98M 95.3M 37.71M 474M 35.21M 34.48M 1.5B
Projected Income Statement - Annual - ImmuCell Corporation
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
26-11-18 $11.25 -0.71% 10,684
26-11-17 $11.33 -0.79% 18,535
26-11-16 $11.42 +6.23% 101,746
26-11-13 $10.75 +5.19% 40,752
26-11-12 $10.22 +0.29% 19,304
  1. Stock Market
  2. Stocks
  3. ICCC Stock